Haverhill Financial Research · October 26, 2026
Summary: Haverhill price target $550 (12 months)
Intuitive Surgical sells robots and then sells the instruments that go into them, and the second part is where the money is. In the third quarter of 2026 revenue reached $3.05 billion, up 22%, with 84% of it recurring. The installed base passed 12,000 da Vinci systems. Reported earnings looked ugly — $1.49 a share against $1.95 — but that is a $450 million antitrust settlement landing in one quarter; on a non-GAAP basis earnings were $3.00, up 25%. The genuine issue is slower: da Vinci procedure growth has stepped down from 17% to 14% over four quarters, and the company has guided full-year growth to roughly 14% to 15% against 18% in 2025. At $452.29 our 12-month price target of $550 is about 22% above the current price, so we rate the shares Buy.
The annuity is the business. Instruments and accessories alone were $1.80 billion, 59% of revenue, and they are consumed whether or not a hospital buys another robot.
Growth is decelerating from a very high base. Procedures grew about 14% in the quarter. That is slower than 2025 and still extraordinary for a device business of this size.
Our view: the market is pricing the deceleration and the arrival of competitors, and underpricing an installed base that compounds instrument revenue for a decade after each placement.
Investment thesis in brief
Our thesis: every system Intuitive places is an annuity, the annuity is growing faster than the placements, and the competitive threat is real but years from mattering at scale.
What we like. The model compounds without needing heroics. The company placed 546 da Vinci systems in the quarter, 315 of them the newer da Vinci 5, and the installed base rose 12% to 12,094. Each of those machines then consumes instruments for every procedure for years. Ion, the lung biopsy platform, grew procedures 31% and its installed base 21%. International is where the next leg sits: da Vinci 5 placements outside the United States were 41 in the quarter against 12 a year earlier, as approvals arrive market by market.
What the market may be missing. Japan. Reimbursement changes in June 2026 accelerated procedure growth there, and da Vinci 5 is now cleared for cardiac procedures in the United States, Europe, India, Japan and Korea. Cardiac is a large category that robotic surgery has barely touched. Korea granted Ion reimbursement in the quarter and management expects more geographies to follow. Reimbursement decisions are slow, unglamorous and the single best predictor of where procedure volumes go next.
What holds us back. Intuitive is deliberately cutting its own instrument pricing. From the first half of 2027 it plans extended-use instruments and volume-based pricing, which management expects to reduce da Vinci instrument revenue per procedure by roughly 3% to 5% once fully implemented, with a China price cut starting in November 2026. That is a sensible defensive move against cheaper rivals, and it still takes revenue out of the most profitable line.
How does the business actually make money?
Three revenue lines, and the proportions matter more than the total.
Instruments and accessories ($1.80 billion, 59% of revenue, up 18%). The blades in the razor-and-blades model. Every procedure consumes them, so this line tracks surgical volume rather than hospital capital budgets.
Systems ($769 million, up about 30%). The robots. Lumpy, capital-budget dependent, and strategically the least important line — each sale is really the acquisition of a future instrument stream.
Services ($482 million, up about 22%). Maintenance contracts on the installed base. Predictable and high margin.
Why 84% recurring is the number to remember. Instruments, services and operating leases together make up 84% of revenue. A hospital that pauses capital spending in a difficult year keeps operating, keeps consuming instruments, and keeps paying for service. That is what makes this a far more defensive business than "surgical robot manufacturer" suggests.
Margins, and the tariff noise within them. Non-GAAP gross margin was 69.9% against 68.0% a year earlier, helped by $27.8 million of tariff refunds worth about $0.06 a share. Full-year guidance still embeds roughly 90 basis points of tariff drag. Non-GAAP operating margin was about 41.6%.
What do the numbers say?
Revenue of $3.05 billion was a record. GAAP operating income was $592.6 million, depressed by the settlement; non-GAAP operating income was $1.27 billion. Cash and investments stood at $6.80 billion, down about $1.83 billion in the quarter after $2.94 billion of share buybacks. The chart below pairs the revenue record with the growth rate that is actually under debate.
Three things investors should know.
The settlement is one-off but real. Intuitive agreed in October 2026 to settle a class action over its surgical robot business for a one-time $450 million payment plus injunctive relief, with no admission of liability. It is subject to court approval. The injunctive part is worth watching: it concerns third-party instrument refurbishing, which touches the instrument annuity directly.
The deceleration is steady, not sudden. About 17%, 17%, 16%, 15% and 14% across the last five quarters. That is a glide, not a cliff, and the company narrowed full-year guidance to roughly 14% to 15%.
Capital is being returned aggressively. $2.94 billion of buybacks in a single quarter, covering 7.8 million shares. The balance sheet carries no debt.
Competition and moat
For twenty years Intuitive had no serious competitor. That is changing, slowly.
Who it competes with. Medtronic's Hugo received clearance for urologic procedures in December 2025 and performed its first US commercial case in February 2026, with filings submitted in June 2026 to expand into general and gynaecologic surgery. Johnson & Johnson's Ottava was submitted to the FDA in January 2026 for upper-abdominal general surgery, with no decision yet. In China, management has described competitive intensity as a factor in its guidance.
Where the moat is real. Surgeons train on a specific system, and hospitals build workflows around the one they own. Twelve thousand installed systems represent thousands of trained teams and a service network nobody else has. The instrument catalogue is deep, the clinical evidence base is twenty years old, and switching means retraining surgeons for marginal benefit.
Where it is thin. A competitor does not need to displace Intuitive to hurt it; it only needs to give hospitals a credible second quote. That is already visible in Intuitive's own pricing decision. And GLP-1 drugs are quietly reducing bariatric surgery volumes — management noted US bariatric cases declining at a high-single-digit rate earlier in the year.
What is it worth?
We value Intuitive Surgical at $550 per share over the next 12 months, to October 2027, as a probability-weighted blend of three cases. That is about 22% above today's price, which supports a Buy.
Our method. We value the company on non-GAAP earnings, because GAAP is distorted by the settlement. By October 2027 the market will be looking at 2028. We grow procedures, apply instrument revenue per procedure net of the planned pricing reset, add systems and service revenue, apply an operating margin, and tax it. We then apply a price-to-earnings multiple and weight the cases 25% bear, 50% base, 25% bull.
Why these numbers. The base case assumes procedure growth settles around 13% — below the current 14% and well below 2025's 18% — and that the pricing reset costs roughly what management has indicated. A 38 times multiple is below the trailing non-GAAP multiple of about 42 times, so the base case already assumes mild de-rating. We are not relying on multiple expansion.
What the price implies. At $452.29 the shares trade at about 42 times trailing non-GAAP earnings of $10.83. The stock rose about 13% in the week after the third-quarter print, so some of the recovery has happened. What remains is the gap between a market pricing low-teens procedure growth and a company that has never yet delivered low-teens procedure growth for a full year.
What are the real risks?
The deceleration continues past our base case. If procedures settle at 11% rather than 13%, the instrument annuity grows more slowly and the multiple compresses at the same time.
The pricing reset costs more than guided. Instruments are 59% of revenue. A 3% to 5% reduction in revenue per procedure is manageable; a larger one, forced by competition, is not.
Competition arrives faster than expected. Hugo is commercial in US urology with general and gynaecologic filings pending, and Ottava's decision is outstanding.
The settlement's injunctive terms. Easier third-party refurbishing of instruments would erode the annuity, and the detail matters more than the $450 million.
GLP-1 drugs. Bariatric procedures were declining at a high-single-digit rate in the United States earlier this year.
Valuation. At roughly 42 times trailing non-GAAP earnings, this is not a cheap stock in any absolute sense. Our Buy is a judgement that the growth justifies it, not that the multiple is low.
What would change our mind?
Our Buy rests on one idea: an installed base that compounds instrument revenue, with competition still years from scale.
Signals that would strengthen the case
Procedure growth stabilising at 14% or better for two consecutive quarters.
Da Vinci 5 placements outside the United States above 60 in a quarter.
New reimbursement decisions for Ion in additional countries.
Instrument revenue per procedure holding through the pricing transition in 2027.
Signals that would move us to Hold or Sell
Procedure growth below 12% in any quarter.
Non-GAAP gross margin below 67%.
A competitor winning a large multi-hospital system contract away from Intuitive.
The price runs above about $640 with no change in our earnings view.
Catalysts to watch
November 2026: the China instrument price reduction begins.
Fourth quarter 2026: planned US submission for the SP vessel sealer.
Mid-January 2027 (Haverhill estimate): preliminary fourth-quarter and full-year results, historically published around the JP Morgan healthcare conference, with first 2027 procedure guidance.
First half of 2027: the extended-use instrument and volume pricing programme begins, pending US clearance.
Date not set: FDA decisions on Medtronic's Hugo expansion filings and Johnson & Johnson's Ottava submission, and court approval of the antitrust settlement.
Sources and disclosures
Every company figure in this report comes from Intuitive Surgical's own filings and results releases, linked below. The analysis, model and price target are Haverhill Financial Research's own work.
Disclosures. Haverhill Financial Research is a publisher of general financial commentary. This report is not personalized investment advice and does not consider any reader's financial situation; readers should do their own research. Price targets are estimates of value, not guarantees. Haverhill ratings follow our published bands: Buy when our 12-month target is at least 15% above the price, Sell when it is at least 15% below, Hold in between. The author of this post does not hold a position in Intuitive Surgical. Price data as of the Nasdaq close on October 23, 2026.
